PD-1 And PD-L1 Inhibitors Market to Record a CAGR of 19.31%, Increasing Prevalence of Cancer to Boost Market Growth – Technavio

NEW YORK, Sept. 23, 2022 /PRNewswire/ — The “PD-1 And PD-L1 Inhibitors Market by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asia, and Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the PD-1 and PD-l1 inhibitors market size between 2021 and 2026 is USD 49.34 billion. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report

Regional Analysis

North America will account for 51% of the market’s growth during the forecast period. This growth is attributed to factors such as the increasing prevalence of various solid tumors and blood-related tumors in the region and the sales of approved therapeutics. However, market growth in this region will be slower than the growth of the market in other regions. The US and Canada are the key countries for the PD-1 and PD-L1 inhibitors market in North America.

Key Market Dynamics

  • Market Driver: The increasing prevalence of cancer is driving the growth of the market. Various novel therapies have been approved in recent years. There is a gap between the demand and supply of these therapies, which has led to a huge unmet need. This has given vendors an opportunity to conduct studies on drugs such as PD-1 and PD-L1 inhibitors. The increasing approvals of these inhibitors are expected to increase their demand, which will drive the growth of the global PD-1 and PD-L1 inhibitors market.
  • Market Challenge: The high cost of available PD-1 and PD-L1 inhibitors will challenge the PD-1 and PD-L1 inhibitors market during the forecast period. The cost of cancer treatment is high, mainly due to laboratory tests, hospitalization, and the administration of novel PD-1 and PD-L1 inhibitor therapeutics. The treatment cost of these therapeutics depends on the stage of cancer. The high cost is leading to a rise in the preference for alternative treatment options such as surgeries, which is hindering the growth of the focused market.

Technavio has identified key trends, drivers, and challenges in the PD-1 and PD-L1 inhibitors market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report

Market Segmentation

By application, the blood-related tumors segment will be the largest contributor to market growth during the forecast period. The growth of this segment is attributed to factors such as the strong prevalence of leukemia and various types of lymphomas globally.

View our FREE PDF sample report for additional insights into the contribution of all the segments and regional opportunities in the report.

Some Companies Mentioned

  • Akeso Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck and Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Shanghai Jhunsi Biosciences Ltd.

Want your report customized? Speak to an analyst and personalize your report according to your needs

Related Reports

Point of Care Diagnostics Market by Product, End-user, and Geography – Forecast and Analysis 2022-2026: The point of care diagnostics market share is expected to increase by USD 13.09 billion from 2021 to 2026.

Pharmacogenomics Market by End-user and Geography – Forecast and Analysis 2022-2026: The pharmacogenomics market share is expected to increase by USD 2.50 billion from 2021 to 2026.

PD-1 And PD-L1 Inhibitors Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 19.31%

Market growth 2022-2026

USD 49.34 billion

Market structure

Fragmented

YoY growth (%)

18.6

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Key Topics Covered

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026 
    • Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary 
    • Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers 
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers 
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants 
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes 
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry 
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition 
    • Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Application

  • 5.1 Market segments 
    • Exhibit 24: Chart on Application – Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Application – Market share 2021-2026 (%)
  • 5.2 Comparison by Application 
    • Exhibit 26: Chart on Comparison by Application
    • Exhibit 27: Data Table on Comparison by Application
  • 5.3 Solid tumors – Market size and forecast 2021-2026
    • Exhibit 28: Chart on Solid tumors – Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Solid tumors – Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Solid tumors – Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Solid tumors – Year-over-year growth 2021-2026 (%)
  • 5.4 Blood-related tumors – Market size and forecast 2021-2026
    • Exhibit 32: Chart on Blood-related tumors – Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on Blood-related tumors – Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Blood-related tumors – Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Blood-related tumors – Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Application 
    • Exhibit 36: Market opportunity by Application ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview 
    • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation 
    • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison 
    • Exhibit 40: Chart on Geographic comparison
    • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America – Market size and forecast 2021-2026
    • Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
    • Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
  • 7.4 Europe – Market size and forecast 2021-2026
    • Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
  • 7.5 Asia – Market size and forecast 2021-2026
    • Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
    • Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
  • 7.7 US – Market size and forecast 2021-2026
    • Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
  • 7.8 Germany – Market size and forecast 2021-2026
    • Exhibit 62: Chart on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on Germany – Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on Germany – Year-over-year growth 2021-2026 (%)
  • 7.9 Canada – Market size and forecast 2021-2026
    • Exhibit 66: Chart on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on Canada – Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on Canada – Year-over-year growth 2021-2026 (%)
  • 7.10 UK – Market size and forecast 2021-2026
    • Exhibit 70: Chart on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on UK – Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on UK – Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on UK – Year-over-year growth 2021-2026 (%)
  • 7.11 France – Market size and forecast 2021-2026
    • Exhibit 74: Chart on France – Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on France – Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on France – Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on France – Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography 
    • Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges 
    • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape 
    • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption 
    • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks 
    • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered 
    • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors 
    • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Amgen Inc. 
    • Exhibit 85: Amgen Inc. – Overview
    • Exhibit 86: Amgen Inc. – Product / Service
    • Exhibit 87: Amgen Inc. – Key offerings
  • 10.4 AstraZeneca Plc 
    • Exhibit 88: AstraZeneca Plc – Overview
    • Exhibit 89: AstraZeneca Plc – Product / Service
    • Exhibit 90: AstraZeneca Plc – Key news
    • Exhibit 91: AstraZeneca Plc – Key offerings
  • 10.5 BeiGene Ltd. 
    • Exhibit 92: BeiGene Ltd. – Overview
    • Exhibit 93: BeiGene Ltd. – Business segments
    • Exhibit 94: BeiGene Ltd. – Key offerings
    • Exhibit 95: BeiGene Ltd. – Segment focus
  • 10.6 Bristol Myers Squibb Co. 
    • Exhibit 96: Bristol Myers Squibb Co. – Overview
    • Exhibit 97: Bristol Myers Squibb Co. – Product / Service
    • Exhibit 98: Bristol Myers Squibb Co. – Key offerings
  • 10.7 Eli Lilly and Co. 
    • Exhibit 99: Eli Lilly and Co. – Overview
    • Exhibit 100: Eli Lilly and Co. – Product / Service
    • Exhibit 101: Eli Lilly and Co. – Key offerings
  • 10.8 F. Hoffmann La Roche Ltd. 
    • Exhibit 102: F. Hoffmann La Roche Ltd. – Overview
    • Exhibit 103: F. Hoffmann La Roche Ltd. – Business segments
    • Exhibit 104: F. Hoffmann La Roche Ltd. – Key news
    • Exhibit 105: F. Hoffmann La Roche Ltd. – Key offerings
    • Exhibit 106: F. Hoffmann La Roche Ltd. – Segment focus
  • 10.9 GlaxoSmithKline Plc 
    • Exhibit 107: GlaxoSmithKline Plc – Overview
    • Exhibit 108: GlaxoSmithKline Plc – Business segments
    • Exhibit 109: GlaxoSmithKline Plc – Key news
    • Exhibit 110: GlaxoSmithKline Plc – Key offerings
    • Exhibit 111: GlaxoSmithKline Plc – Segment focus
  • 10.10 Merck and Co. Inc. 
    • Exhibit 112: Merck and Co. Inc. – Overview
    • Exhibit 113: Merck and Co. Inc. – Business segments
    • Exhibit 114: Merck and Co. Inc. – Key news
    • Exhibit 115: Merck and Co. Inc. – Key offerings
    • Exhibit 116: Merck and Co. Inc. – Segment focus
  • 10.11 Merck KGaA 
    • Exhibit 117: Merck KGaA – Overview
    • Exhibit 118: Merck KGaA – Business segments
    • Exhibit 119: Merck KGaA – Key news
    • Exhibit 120: Merck KGaA – Key offerings
    • Exhibit 121: Merck KGaA – Segment focus
  • 10.12 Sanofi 
    • Exhibit 122: Sanofi – Overview
    • Exhibit 123: Sanofi – Business segments
    • Exhibit 124: Sanofi – Key news
    • Exhibit 125: Sanofi – Key offerings
    • Exhibit 126: Sanofi – Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist 
    • Exhibit 127: Inclusions checklist
    • Exhibit 128: Exclusions checklist
  • 11.3 Currency conversion rates for US$ 
    • Exhibit 129: Currency conversion rates for US$
  • 11.4 Research methodology 
    • Exhibit 130: Research methodology
    • Exhibit 131: Validation techniques employed for market sizing
    • Exhibit 132: Information sources
  • 11.5 List of abbreviations 
    • Exhibit 133: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pd-1-and-pd-l1-inhibitors-market-to-record-a-cagr-of-19-31-increasing-prevalence-of-cancer-to-boost-market-growth—-technavio-301630698.html

SOURCE Technavio

PD-1 And PD-L1 Inhibitors Market to Record a CAGR of 19.31%, Increasing Prevalence of Cancer to Boost Market Growth - Technavio WeeklyReviewer

PR Newswire Science News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer